862 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
3 Large-Cap Stocks Hitting 52-Week Highs: Are They Buys? https://www.fool.com/investing/2019/03/26/3-large-cap-stocks-hitting-52-week-highs-are-they.aspx?source=iedfolrf0000001 Mar 26, 2019 - Can these big high-flying stocks keep the momentum going?
Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition http://www.zacks.com/stock/news/362782/bristol-myers-celgene-buyout-still-uncertain-amid-opposition?cid=CS-ZC-FT-362782 Mar 21, 2019 - The acquisition deal between Bristol-Myers and Celgene faces opposition from stakeholders of Bristol-Myers. The future of the deal depends on the outcome of the Special Meeting in April.
Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $15. ... http://www.gurufocus.com/news/835656/merck--co-inc-mrk-chairman-president--ceo-kenneth-c-frazier-sold-158-million-of-shares Mar 20, 2019 - Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $15.8 million of Shares, Stocks: MRK, release date:Mar 20, 2019
Glaxo Presents Encouraging Data on Endometrial Cancer Drug http://www.zacks.com/stock/news/362265/glaxo-presents-encouraging-data-on-endometrial-cancer-drug?cid=CS-ZC-FT-362265 Mar 20, 2019 - Glaxo (GSK) presents encouraging data from phase I/II study on endometrial cancer drug, dostarlimab.
Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer http://www.zacks.com/stock/news/361461/roches-tecentriq-gets-fda-approval-for-difficult-lung-cancer?cid=CS-ZC-FT-361461 Mar 19, 2019 - Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).
Top Research Reports for Merck, Adobe & Broadcom http://www.zacks.com/research-daily/360711/top-research-reports-for-merck-adobe-broadcom?cid=CS-ZC-FT-360711 Mar 18, 2019 - Top Research Reports for Merck, Adobe & Broadcom
AstraZeneca Up This Year on New Drugs & Pipeline Progress http://www.zacks.com/stock/news/359997/astrazeneca-up-this-year-on-new-drugs-pipeline-progress?cid=CS-ZC-FT-359997 Mar 18, 2019 - AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
Merck's Keytruda Gets EU Approval for Difficult Lung Cancer http://www.zacks.com/stock/news/359869/mercks-keytruda-gets-eu-approval-for-difficult-lung-cancer?cid=CS-ZC-FT-359869 Mar 15, 2019 - Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.
Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others http://www.zacks.com/stock/news/359854/pharma-stock-roundup-regulatory-updates-from-mrk-pfe-jj-agn-others?cid=CS-ZC-FT-359854 Mar 15, 2019 - Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.
Lilly's Cyramza Successful in Phase III First-Line NSCLC Study http://www.zacks.com/stock/news/359294/lillys-cyramza-successful-in-phase-iii-first-line-nsclc-study?cid=CS-ZC-FT-359294 Mar 13, 2019 - Lilly's (LLY) cancer drug, Cyramza, in combination with erlotinib significantly delays disease progression in a phase III study on previously untreated patients with EGFR-mutated metastatic NSCLC.

Pages: 1...4567891011121314...87

<<<Page 9>